B150 but over the baseline value by more than 100, or acute complications requiring surgery. The inclusion criteria were fulfilled by 178 patients. The median follow up was 23 Up till now, the results of research for a maintenance treatment in quiescent CD patients are contradictory and may depend on patient characteristics. Although mesalamine has recently been reported to be an effective maintenance treatment in quiescent CD patients,1 this result is still equivocal. The only confirmation was reported among patients who had a relapse-free interval of more than three months.2 However, Gendre et al3 reported that mesalamine had no effect in this group of patients and was only effective among patients treated within three months after the achievement of remission. Again, a recent interim analysis disagreed with this last viewpoint. 4 Because of these contradictory data, it remains unclear whether mesalamine is effective as a maintenance treatment and, if so, in which subgroups of quiescent CD patients.
Risk factors of relapse in quiescent CD patients are poorly known. Many studies have investigated the possible correlation between the CDAI5 and certain biological factors measured at the same time. However, even a high correlation does not provide any information concerning the prediction of a future relapse. Although some investigators suggested that certain laboratory parameters might predict the course of the disease, their results were based on non-comparative studies with a small number of patients.6 7 According to their PS value at entry to the study, patients were classified into three groups: a good prognosis group had a score <0 5, which corresponds to patients having none or only one of the four bad prognostic factors, an intermediate group had a score between 0.5 and 1.5 (patients having two bad prognostic factors), and a poor prognosis group had a score 2 1.5 (three or four bad prognostic factors). Table  III provides further information about these three groups according to patient characteristics at entry in the study and Fig 2 presents the corresponding time to relapse curves.
Discussion
The prediction of relapse of Crohn's disease is a persistent dream of both clinicians and patients. If achieved, this would allow the design of clinical trials aiming at an early treatment of the forthcoming relapse.
Time to relapse Our study showed that the relapse free probability after two years from entry to the study was 46%. This estimate was 63% for the levamisole trial, 50% for the mesalamine trial, and could not be estimated separately for the corticotherapy trial because the follow up was limited to 18 months. Noteworthy, the relapse free probability in this trial was estimated to be only 42% at 18 months. These differences resulted from the fact that the distribution of patients in the three prognostic groups was different in the three trials. The levamisole trial had 10 (32%), 13 (42%), and eight (26%) patients in the good, intermediate, and bad prognosis groups, respectively. The corresponding figures in the corticotherapy trial were 0 (0%/o) 21 (330/o), and 43 (670/o) and for the mesalamine trial they were 13 (17%), 31 (40%), and 33 (43%).
The two year relapse free probability in the NCCDS was about 60%. 8 Byar.16 Some statisticians may prefer the median value as a cut off point but usually it is the patients with extreme values who behave differently with respect to the end point of interest. Others may like what they call the 'optimal cut off point' -that is, the cut off point that leads to the smallest p value. But in that case the 'optimal' cut off point will probably not be optimal for another data set.
Biologicalfactors
Six biological factors regarded to be of potential prognostic value were studied. Other possible prognostic factors such as C reactive protein, orosomucoide, a( antitrypsin, serum 30 iron, etc, were not available in our trials. Some of these parameters were reported to be predictors of further disease activity by s other investigators: the C reactive protein, 6 7 orosomucoide, and cxl antitrypsin.7 Both pubiate lications were based on a small number of patients (five and 33 respectively), however, and were non-comparative -that is, the variation of these biological parameters in the group of patients who did not relapse was not provided. Also, Wright et al,7 reported that some mne patients were included more than once in their no study. In the NCCDS27 a favourable outcome of as measured by a change in CDAI had a posihis tive correlation with the leucocyte count and a ent negative correlation with albumin, both her measured at randomisation among quiescent nts CD patients receiving placebo. The authors nd were aware, however, that statistical signifirial cance was probably achieved because of the an-large number of variables tested, rather than ties because of any profound biological implica-)us tions. Recently, Prantera et al 2 mentioned that nto only the presence of laboratory signs of inflammation was significantly correlated with relapse without detailing these signs. Our results showed that the packed cell volume and weight loss did not show any prognostic value, the which confirms the NCCDS results among ires patients receiving placebo.8 wo Sachar30 stated that 'the list of tests proro-posed as either predictors or markers of disease me activity is growing longer every day. The length Lnd of the list is, unfortunately, inversely proporion tional to the adequacy of any of its compothe nents'. Our results showed that none of the 7-29 biological factors were significant in either the by univariate or multivariate analyses. This is pse reasonable as the median time to relapse is the probably too long to be affected by biological fits parameters measured at entry. In other words, not it is difficult to consider that a trans-sectional biological measurement might affect an event der that has a median free duration of more than t is 20 months. Few investigators were aware of o a this pitfall and analysed biological data the measured one to three months before the ges relapse.6 7 A definitive answer may be provided Les-by collecting repeatedly laboratory measures dies every one to two months during the course of est. the disease. The analysis of these data should the be performed using appropriate techniques, for e is example, as time dependent covariates in the by Cox proportional hazards regression model. This was taken into account in the design of the current GETAID double blind randomised trial comparing 5-aminosalicylic acid (4 g/day) with placebo. This trial will be analysed towards the end of 1994.
Disease topography Although patients with colonic involvement had three times the risk of relapse relative to patients with ileitis only, it is necessary to take into consideration the small number of patients with disease confined to the ileum and the small number of relapses in this group. This is reflected in the wide 95% confidence intervals for the relative risk (1. It was shown that a short interval since first symptoms was positively correlated to the outcome after adjusting for age but not alone. This was confirmed by the results of bootstrapping and also by the results of the second multivariate model using the time calculated from the end of the last relapse. In our opinion, the effect of the interval since first symptoms in a univariate analysis was completely masked by the effect of age. Stratification for age to take into account its effect shows that patients with a short interval since first symptoms had a significantly better prognosis (RR=0.5, 95% CI: 0.3 to 0.9, p=0018). This means that age corrects the effect of the interval since first symptoms. In other words, the importance of interval since first symptoms becomes evident only once age is taken into account. This also emphasises the importance of multivariate analysis as an essential element of the data analysis. Although the ECCDS reported a favourable prognosis for patients with a long duration of symptoms, its prognostic value when taking age into account was not tested. 9 We should also keep in mind that age, whether at first symptoms, at diagnosis, or at consultation, and intervals since first symptoms and diagnosis are highly correlated with each other. Further investigation on another set of data is necessary for a better understanding of the prognostic value of these variables.
Interval since the end of the previous relapse A prolonged pre-study remission was positively correlated to a prolonged time to relapse. Similar results were reported by other investigators.2 This finding reflects a clinical finding that has led the GETAID to introduce the prestudy duration of remission as an element in the definition of risk groups in two recent randomised clinical trials (Gendre et al3 and a current clinical trial). The choice of cut off points in these two trials was somewhat arbitrary, however, and based only on clinical experience, even if this variable has been shown to be an important prognostic factor.3
Previous surgery or treatmentfor CD We did not find any prognostic value for previous intestinal resection. The ECCDS reported that patients with a previous bowel resection had a less favourable outcome,9 whereas other investigators reported the opposite.2 The NCCDS results showed that patients who entered the trial with recurrent disease after complete resection ranked significantly better in outcome then patients who entered with no prior history of surgery or after an incomplete resection.8 Our results confirm the ECCDS findings, which showed no prognostic difference between previously untreated and treated patients.9 The drug(s) used in the previous relapse to achieve remission were not investigated in this study. To our knowledge, however, it has never been shown or even claimed in the context of a randomised clinical trial for active Crohn's disease, that a specific drug used to achieve remission has any influence of the duration of this remission.
CDAI
We found no statistically significant prognostic value for the CDAI. The NCCDS showed that a CDAI <200 was associated with a favourable outcome in placebo treated patients.8 Again that was among patients with active disease at randomisation. Wright and coauthors7 reported that the CDAI increases in the three months preceding the attack but no comparisons were provided of the CDAI variation in the group of patients who did not relapse. This result has not been confirmed by other investigators despite the fact that the CDAI is the most frequently used index in clinical trials of CD.
Multivariate results Model validation is a necessary but often neglected task. Up to now, in the field of CD, only one index has been validated using an independent data set.34 To assure the validity of the conclusions based on any suggested model, investigating its stability should be an important step in the analysis. The bootstrap technique is a useful and simple tool to investigate the variation in the variable constituting the model. Our results showed that the proposed model is stable, that is, the most frequently selected variables using the bootstrap technique were those selected in the original model. Nevertheless, validation on an independent data set is foreseen.
Risk groups
The identification of risk groups will improve the design of clinical trials among quiescent CD patients. Patients entered in clinical trials tend to be quite heterogeneous. In clinical trials that mix high and low risk patients, a possible bias when assessing treatment efficacy may occur because of an imbalance of the percentage of high risk patients in each treatment arm. Stratification by risk group at randomisation would highly minimise the possibility of such a bias. Nevertheless, even if such an imbalance does not exist, a lack of power in detecting treatment differences may result from the inclusion of low and intermediate risk patients as all treatments may show roughly the same efficacy in these patients. In other words, clinical trials based on a homogenous group of high risk patients are more powerful in detecting a difference in treatment efficacy. The trial conducted by our group3 provides a clear example, as patients were stratified at randomisation by the pre-trial remission period (<3 months versus 3-24 months). The treatment (mesalamine 2 g/day) was only effective among patients who had a short pre-trial remission. Identifying risk groups also allows different trials to be carried out in quiescent CD patients with good or poor prognoses.
Based on our findings the following conclusions may be made: (a) a young age whether at first symptoms, at diagnosis, or at consultation is related to a high risk of clinical relapse in quiescent (not induced by surgery) CD patients; (b) the prognostic value of the interval since first symptoms and the interval since diagnosis and their relation with age needs further investigation on an independent group of patients; (c) a short interval since the previous relapse is associated with a poor prognosis; (d) colonic involvement is associated with a bad prognosis. This study provides the possibility for the design of powerful clinical trials in quiescent CD patients with a high risk of relapse.
